Sickle Cell Thalassemia
8
1
3
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease
Autologous Testicular Tissue Transplantation
Epidemiology of Silent and Overt Strokes in Sickle Cell Disease
PINPOINT: Gaming Technology for SCD Pain
Clinical and Laboratory Characteristics of Sickle Cell Anemia Patients Admitted With Fever
Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia
Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia
Long Term Follow up in Sickle Cell Patients Treated by Hydroxyurea